Filtered By:
Condition: Atrial Fibrillation
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 192 results found since Jan 2013.

Efficacy and Safety of Novel Oral Anticoagulants in Patients with Cervical Artery Dissections
We report on the use, safety, and efficacy of NOACs in the treatment of CAD. Methods: We retrospectively identified patients diagnosed with CAD at a single academic center between January 2010 and August 2013. Patients were categorized by their antithrombotic treatment at hospital discharge with a NOAC (dabigatran, rivaroxaban, or apixaban), traditional anticoagulant (AC: warfarin or treatment dose low-molecular weight heparin), or antiplatelet agent (AP: aspirin, clopidogrel, or aspirin/extended-release dypyridamole). Using appropriate tests, we compared the baseline medical history, presenting clinical symptoms and initi...
Source: Cerebrovascular Diseases - November 12, 2014 Category: Neurology Source Type: research

Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation
As atrial fibrillation (AF) substantially increases the risk of stroke and other thromboembolic events, most AF patients require appropriate antithrombotic prophylaxis. Oral anticoagulation (OAC) with either dose-adjusted vitamin K antagonists (VKAs) (eg, warfarin) or non-VKA oral anticoagulants (eg, dabigatran, apixaban, rivaroxaban) can be used for this purpose unless contraindicated. Therefore, risk assessment of stroke and bleeding is an obligatory part of AF management, and risk has to be weighed individually. Antiplatelet drugs (eg, aspirin and clopidogrel) are inferior to OAC, both alone and in combination, with a c...
Source: Cardiology Clinics - September 1, 2014 Category: Cardiology Authors: Mikhail S. Dzeshka, Gregory Y.H. Lip Source Type: research

Decennial Analysis of Interventional Left Atrial Appendage Closure
Conclusion: During LTFU after LAAC in patients with non‐valvular AF lower event rates than expected are observed for both thrombembolic and bleeding complications This article is protected by copyright. All rights reserved
Source: Journal of Cardiovascular Electrophysiology - April 1, 2015 Category: Cardiology Authors: Boris Schmidt, Stefano Bordignon, Alexander Fuernkranz, Laura Perrotta, Detlef Scherer, KR Julian Chun Tags: Original Article Source Type: research

Cost-Effectiveness of A Left Atrial Appendage Closure Device In Patients With Non-Valvular Atrial Fibrillation Unable or Unwilling to Tolerate Oral Anticoagulant Therapy In Italy And Spain
Approximately 18-20% of non-valvular atrial fibrillation (NVAF) patients are unable or unwilling to tolerate oral anticoagulant therapy (OAT), leaving them at risk of stroke. Left atrial appendage closure (LAAC) device offers an alternative stroke risk reduction strategy that enables the majority of patients to discontinue long-term systematic OAT. Acknowledging both potential improvements in health outcomes and additional upfront implantation costs of a LAAC device, this study considers the lifetime costs and benefits of LAAC compared to aspirin plus clopidogrel (A+C) in high-risk NVAF patients ineligible or unwilling to ...
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Amin, I Cruz González, V Reddy, D Holmes, S Berti, A Iñiguez Romo, L De Deppo, V Priest, M Simmonds, C Lee, M Wasserman, A Margonato Source Type: research

Clinical Relevance of Anticoagulation and Dual Antiplatelet Therapy to the Outcomes of Patients With Atrial Fibrillation and Recent Percutaneous Coronary Intervention With Stent.
CONCLUSIONS: TT, DT and DAPT displayed similar efficacy and safety. Although the superiority of OAC vs. DAPT for stroke prevention in AF patients has been demonstrated by previous randomized trials, a smaller frequency of high thromboembolic risks' features in DAPT group of the present study may have prevented the observation of a higher incidence of ischemic stroke in this group. PMID: 26767085 [PubMed]
Source: Clin Med Res - January 18, 2016 Category: Research Authors: De Vecchis R, Cantatrione C, Mazzei D Tags: J Clin Med Res Source Type: research

A Randomized Trial to Compare the Safety of Rivaroxaban versus Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome: The Design of the GEMINI-ACS-1 Phase II Study
Publication date: Available online 18 January 2016 Source:American Heart Journal Author(s): Thomas J. Povsic, Matthew T. Roe, E. Magnus Ohman, Philippe Gabriel Steg, Stefan James, Alexei Plotnikov, Hardi Mundl, Robert Welsh, Christoph Bode, C. Michael Gibson Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy. The factor Xa inhibitor rivaroxaban was shown ...
Source: American Heart Journal - January 19, 2016 Category: Cardiology Source Type: research

A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study
Publication date: April 2016 Source:American Heart Journal, Volume 174 Author(s): Thomas J. Povsic, Matthew T. Roe, Erik Magnus Ohman, Philippe Gabriel Steg, Stefan James, Alexei Plotnikov, Hardi Mundl, Robert Welsh, Christoph Bode, Charles Michael Gibson Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy. The factor Xa inhibitor rivaroxaban was shown to ...
Source: American Heart Journal - February 23, 2016 Category: Cardiology Source Type: research

Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation
As atrial fibrillation (AF) substantially increases the risk of stroke and other thromboembolic events, most AF patients require appropriate antithrombotic prophylaxis. Oral anticoagulation (OAC) with either dose-adjusted vitamin K antagonists (VKAs) (eg, warfarin) or non-VKA oral anticoagulants (eg, dabigatran, apixaban, rivaroxaban) can be used for this purpose unless contraindicated. Therefore, risk assessment of stroke and bleeding is an obligatory part of AF management, and risk has to be weighed individually. Antiplatelet drugs (eg, aspirin and clopidogrel) are inferior to OAC, both alone and in combination, with a c...
Source: Heart Failure Clinics - March 9, 2016 Category: Cardiology Authors: Mikhail S. Dzeshka, Gregory Y.H. Lip Source Type: research

Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.
CONCLUSIONS: There is evidence from RCTs to suggest that neither oral anticoagulation with warfarin or platelet inhibition with aspirin is better for mortality in systolic heart failure with sinus rhythm (high quality of the evidence for all-cause mortality and moderate quality of the evidence for non-fatal cardiovascular events and major bleeding events). Treatment with warfarin was associated with a 20% reduction in non-fatal cardiovascular events but a twofold higher risk of major bleeding complications (high quality of the evidence). We saw a similar pattern of results for the warfarin versus clopidogrel comparison (lo...
Source: Cochrane Database of Systematic Reviews - September 14, 2016 Category: Journals (General) Authors: Shantsila E, Lip GY Tags: Cochrane Database Syst Rev Source Type: research

Quality of Care Provided by Board-Certified Versus Non-Board-Certified Psychiatrists and Neurologists
Conclusions: The authors demonstrated the feasibility of linking physician information with patient records to construct quality measures from electronic claims data, but there may be only minimal differences in the quality of care between BC and nBC psychiatrists and neurologists, or there may be a difference that could not be measured with the quality measures used.
Source: Academic Medicine - December 29, 2016 Category: Universities & Medical Training Tags: Research Reports Source Type: research

Rates of Adverse Events in the Very Old: A Community Anticoagulation Clinic Study (P6.291)
Conclusions:The very old still achieve minimum TTR to experience anticoagulation benefits. Patients older than 95 are at appreciably increased risk of hemorrhage, while ischemic events were overrepresented in ages 90–95. Future work aims to determine risk factors for thrombotic and hemorrhagic events in the very old.Disclosure: Dr. Stanley has nothing to disclose. Dr. Knight has nothing to disclose. Dr. Stein has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Stanley, M., Knight, C., Stein, R. Tags: Prevention of Cerebrovascular Disease Source Type: research

The challenge of coprescription of antiplatelet therapy and oral anticoagulants
The coexistence of symptomatic carotid artery stenosis and nonvalvular atrial fibrillation (NVAF) in the recently reported 85year old man [1] bears out the findings of the study which documented a 24.3% prevalence of high-grade (50% or more) carotid artery stenosis among 103 consecutive NVAF patients (mean age 69) who presented with stroke [2]. Among these patients with high-grade stenosis 66.7% had stenosis ipsilateral to the cerebral infarct [2]. Given the fact that patients with symptomatic carotid artery stenosis are at high risk of stroke recurrence and/or worsening neurological disability during the first 14days foll...
Source: The American Journal of Emergency Medicine - May 22, 2017 Category: Emergency Medicine Authors: Oscar M.P. Jolobe Source Type: research

Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents
Conclusions Among patients receiving DES implantation, AF was not rare and was associated with increased ischemic and bleeding risk. In patients with AF, triple therapy was not associated with decreased ischemic events but was associated with increased bleeding risk compared to DAPT.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - June 5, 2017 Category: Cardiology Authors: Choi, H.-I., Ahn, J.-M., Kang, S. H., Lee, P. H., Kang, S.-J., Lee, S.-W., Kim, Y.-H., Lee, C. W., Park, S.-W., Park, D.-W., Park, S.-J. Tags: Coronary Source Type: research

The safety and efficacy of oral anticoagulants with dual versus single antiplatelet therapy in patients after percutaneous coronary intervention: A meta-analysis
Conclusion: In patients on OAC undergoing PCI with stent implantation, compared with DT, TT shows equal effectiveness in terms of MACE, stroke, all-cause mortality, and stent thrombosis and lower risks of myocardial infarction and major bleeding. However, similar efficacy and safety outcomes were observed between the TT group and the OAC along with clopidogrel group.
Source: Medicine - September 1, 2017 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Evaluation of the Safety and Efficacy of an Edoxaban-based Antithrombotic Regimen in Patients with Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) with Stent Placement: Rationale and Design of the ENTRUST-AF PCI Trial
Publication date: Available online 23 October 2017 Source:American Heart Journal Author(s): Pascal Vranckx, Thorsten Lewalter, Marco Valgimigli, Jan G. Tijssen, Paul-Egbert Reimitz, Lars Eckardt, Hans-Joachim Lanz, Wolfgang Zierhut, Rüdiger Smolnik, Andreas Goette Background The optimal antithrombotic treatment after percutaneous coronary intervention (PCI) with stenting in patients with atrial fibrillation (AF) is unknown. In the ENGAGE AF-TIMI 48 trial, edoxaban was non-inferior to a vitamin-K antagonist (VKA) with respect to the prevention of stroke or systemic embolism and was associated with significantly lower rate...
Source: American Heart Journal - October 23, 2017 Category: Cardiology Source Type: research